Literature DB >> 25387192

Life expectancy in patients with chronic HCV infection and cirrhosis compared with a general population.

Adriaan J van der Meer1, Heiner Wedemeyer2, Jordan J Feld3, Jean-François Dufour4, Stefan Zeuzem5, Bettina E Hansen1, Harry L A Janssen1.   

Abstract

Entities:  

Mesh：

Year:  2014        PMID： 25387192     DOI： 10.1001/jama.2014.12627

Source DB:  PubMed          Journal:  JAMA        ISSN： 0098-7484            Impact factor:   56.272


× No keyword cloud information.
  34 in total

1.  Safety and Effectiveness of Ledipasvir and Sofosbuvir, With or Without Ribavirin, in Treatment-Experienced Patients With Genotype 1 Hepatitis C Virus Infection and Cirrhosis.

Authors:  Joseph K Lim; Ann Marie Liapakis; Mitchell L Shiffman; Anna S Lok; Stefan Zeuzem; Norah A Terrault; James S Park; Charles S Landis; Mohamed Hassan; Joel Gallant; Alexander Kuo; Paul J Pockros; Monika Vainorius; Lucy Akushevich; Larry Michael; Michael W Fried; David R Nelson; Ziv Ben-Ari
Journal:  Clin Gastroenterol Hepatol       Date:  2018-01-03       Impact factor: 11.382

2.  [Treatment of hepatitis C].

Authors:  M D Schneider; B Kronenberger; S Zeuzem; C Sarrazin
Journal:  Internist (Berl)       Date:  2015-04       Impact factor: 0.743

Review 3.  Hepatocellular Cancer: Is Recurrence Inevitable?

Authors:  Levent Doganay
Journal:  J Gastrointest Cancer       Date:  2017-09

Review 4.  Antiviral Therapy in Patients with Viral Hepatitis and Hepatocellular Carcinoma: Indications and Prognosis.

Authors:  Christoph Roderburg; Frank Tacke; Christian Trautwein
Journal:  Visc Med       Date:  2016-04-05

Review 5.  Treatment of hepatitis C in difficult-to-treat patients.

Authors:  Peter Ferenci
Journal:  Nat Rev Gastroenterol Hepatol       Date:  2015-04-21       Impact factor: 46.802

6.  Dialysis-requiring acute kidney injury among hospitalized adults with documented hepatitis C Virus infection: a nationwide inpatient sample analysis.

Authors:  G N Nadkarni; A Patel; P K Simoes; R Yacoub; N Annapureddy; S Kamat; I Konstantinidis; P Perumalswami; A Branch; S G Coca; C M Wyatt
Journal:  J Viral Hepat       Date:  2015-07-20       Impact factor: 3.728

Review 7.  Direct-acting antiviral agents for HCV infection affecting people who inject drugs.

Authors:  Jason Grebely; Behzad Hajarizadeh; Gregory J Dore
Journal:  Nat Rev Gastroenterol Hepatol       Date:  2017-08-23       Impact factor: 46.802

8.  Recommendations for the management of hepatitis C virus infection among people who inject drugs.

Authors:  Jason Grebely; Geert Robaeys; Philip Bruggmann; Alessio Aghemo; Markus Backmund; Julie Bruneau; Jude Byrne; Olav Dalgard; Jordan J Feld; Margaret Hellard; Matthew Hickman; Achim Kautz; Alain Litwin; Andrew R Lloyd; Stefan Mauss; Maria Prins; Tracy Swan; Martin Schaefer; Lynn E Taylor; Gregory J Dore
Journal:  Int J Drug Policy       Date:  2015-07-17

9.  Excluding people who use drugs or alcohol from access to hepatitis C treatments – Is this fair, given the available data?

Authors:  Jason Grebely; Bridget Haire; Lynn E Taylor; Paul Macneill; Alain H Litwin; Tracy Swan; Jude Byrne; Jules Levin; Philip Bruggmann; Gregory J Dore
Journal:  J Hepatol       Date:  2015-08-04       Impact factor: 25.083

10.  Risk of End-Stage Liver Disease in HIV-Viral Hepatitis Coinfected Persons in North America From the Early to Modern Antiretroviral Therapy Eras.

Authors:  Marina B Klein; Keri N Althoff; Yuezhou Jing; Bryan Lau; Mari Kitahata; Vincent Lo Re; Gregory D Kirk; Mark Hull; H Nina Kim; Giada Sebastiani; Erica E M Moodie; Michael J Silverberg; Timothy R Sterling; Jennifer E Thorne; Angela Cescon; Sonia Napravnik; Joe Eron; M John Gill; Amy Justice; Marion G Peters; James J Goedert; Angel Mayor; Chloe L Thio; Edward R Cachay; Richard Moore
Journal:  Clin Infect Dis       Date:  2016-08-09       Impact factor: 9.079
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.